Granted IMC-G.A.P. Equivalency Certification by Control Union (“CU”)Milestone to export to Israel and EU-GMP facilities in ...

The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a biosimilar to reference p ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...

Pharmaceutical Market Size and Growth 2025 to 2034The global pharmaceutical market size was valued at USD 1,607.07 billion in ...

Nabota has previously obtained product approval from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA ... in Korea As the competition in artificial intelligence ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Both the US Food and Drug Administration (FDA), through the Orphan Drug Act, and the European Medicines Agency (EMA), through ... alongside the International Rare Diseases Research Consortium ...